Overview

Study Comparing Paclitaxel Plus Carboplatin Versus Anthracyclines Followed by Docetaxel as Adjuvant Chemotherapy for Triple Negative Breast Cancer (PATTERN)

Status:
Completed

Trial end date:
2016-04-20

Target enrollment:

Participant gender:

Summary

This is a prospective, multisite, randomized, open-lable Phase III clinical trial (PATTERN study) comparing Paclitaxel Plus Carboplatin versus Anthracyclines followed by docetaxel as adjuvant chemotherapy for triple negative breast cancer

Phase:

Phase 3

Details

Lead Sponsor:

Fudan University

Treatments:

Albumin-Bound Paclitaxel
Carboplatin
Cyclophosphamide
Docetaxel
Epirubicin
Fluorouracil
Paclitaxel